AstraZeneca (CHIX:AZNL) FFO


CHIX:AZNL AstraZeneca PLC CHIX:AZNL
88 GF Score
Price £144.74
GF Value £134.60
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is AstraZeneca FFO?

FFO (Funds from operations) only applies to REITs.

CHIX:AZNL
88GF Score
AstraZeneca PLC CHIX:AZNL
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AstraZeneca (CHIX:AZNL) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be overvalued. The current stock price of £144.74 is trading 7.5% above its estimated GF Value™ of £134.60. GuruFocus considers AstraZeneca to be Fairly Valued.

Key valuation signals for CHIX:AZNL:

  • FFO:
  • GF Value™: £134.60 vs. price of £144.74 (7.5% above fair value)
  • GF Score™: 88/100 with 5 warning signs

No single metric tells the full story. See the CHIX:AZNL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
88GF Score

Get the complete analysis for CHIX:AZNL

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£144.74
Price
£134.60
GF Value